Accreditation/
Credit Designation
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Acknowledgment of Commercial Support
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
Oncology Best Practice™: The Latest Advances on MET Inhibitors for Treatment of Advanced NSCLC Along Lines of Care
Oncology Best Practice™: The Latest Advances on MET Inhibitors for Treatment of Advanced NSCLC Along Lines of Care
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at [email protected]
Start date: April 30, 2021
Overview
Oncology Best Practices™ is a series of interactive meetings hosted by leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. Nationally renowned lung cancer experts will lead this meeting. The live session begins with a brief update that will review advances in the medical management of advanced non–small cell lung cancer (NSCLC), including the identification of predictive molecular markers like MET. The incorporation of optimal testing strategies allows for targeted intervention and fosters personalized patient care. This activity will utilize a variety of formats, including presentation of new data, clinical scenarios exploring the evidence behind treatment decisions, adverse event management, and a faculty Q&A to encourage peer-to-peer and peer-to-expert interactions and the sharing of best practices. At the conclusion of the program, you will have time to ask the participating faculty questions, allowing for regional and institutional considerations to be brought up in an intimate environment.
Benefits of Attending
- Interact with a nationally recognized lung cancer expert and local peers at each meeting.
- Explore the application of clinical data and expert guidelines to common challenging patient scenarios.
- Develop strategies for managing adverse events associated with MET inhibitors.
- Learn about ongoing clinical trial opportunities for your patients with NSCLC.
Acknowledgment of Commercial Support
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
Target Audience
This educational activity is directed toward a global audience of medical oncologists, pulmonologists, thoracic surgeons, and pathologists who treat patients with NSCLC. Physician assistants, nurse practitioners, pharmacists, researchers, and other health care professionals interested in the treatment of NSCLC are invited to participate.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Describe the biological role of MET alterations in untreated NSCLC and as a resistance mechanism to EGFR-targeted therapy for NSCLC.
- Delineate tumor tissue testing and liquid biopsy strategies that should be undertaken prior to front-line treatment and in relapsed NSCLC settings to inform clinical decision-making among patients with MET alterations
- Evaluate clinical trial safety and efficacy data on single-agent or combination strategies with MET-targeted agents that have been evaluated for the treatment of NSCLC.
Program Chair
Joyce Zeff Chair in Lung Cancer Research
Director of Thoracic Oncology,
University of Colorado
Aurora, CO
